Supreme Court says retailers can sue FDA over vape bans, citing NCLA in key ruling

Why did the Supreme Court’s June 2025 ruling involve vaping bans and judicial access to FDA orders?

In a closely watched regulatory case, the U.S. Supreme Court issued a landmark ruling on June 20, 2025, affirming that retailers affected by federal regulatory actions—specifically bans on the sale of certain e-cigarette products—have the right to seek judicial review. The decision in Food and Drug Administration et al. v. R.J. Reynolds Vapor Company et al. preserves the right of affected third parties, such as retailers and distributors, to challenge Food and Drug Administration (FDA) orders in federal court even if they were not part of the original agency proceeding.

The ruling directly upholds a prior decision by the U.S. Court of Appeals for the Fifth Circuit and reinforces the precedent that federal statutes such as the Family Smoking Prevention and Tobacco Control Act (TCA) and the Administrative Procedure Act (APA) afford judicial review to any party “adversely affected or aggrieved” by agency action. The New Civil Liberties Alliance (NCLA), a nonprofit civil liberties organization focused on limiting administrative overreach, submitted an amicus curiae brief that was explicitly cited in the Court’s written opinion, further elevating the significance of this case for administrative and constitutional law.

The core legal question was whether retailers—who faced immediate commercial losses from the FDA’s refusal to authorize a specific product for sale—had standing to challenge that denial in court. The Supreme Court, by siding with the retailers, placed new limits on how narrowly agencies like the FDA may interpret legal standing under federal law.

How did this legal dispute between FDA and retailers over vaping product bans begin in lower courts?

The case originated from the FDA’s rejection of a premarket tobacco application (PMTA) submitted by R.J. Reynolds Vapor Company for its “Vuse” branded e-cigarettes. Under the TCA, which Congress enacted in 2009, the FDA must evaluate and approve certain new tobacco products, including e-cigarettes, before they can be legally marketed in the United States. While an application is under review, companies are often permitted to sell the product temporarily.

In this instance, after the FDA formally denied R.J. Reynolds Vapor Company’s PMTA, multiple retailers—including RJR Vapor Company L.L.C., Avail Vapor Texas L.L.C., and the Mississippi Petroleum Marketers and Convenience Stores Association—were barred from continuing to sell the Vuse e-cigarettes. These retailers filed a petition in the Fifth Circuit, arguing that the FDA’s decision had “adversely affected” their businesses through loss of sales and inventory devaluation.

The FDA responded by seeking to dismiss the petition, asserting that only the original applicant (R.J. Reynolds Vapor Company) could be deemed adversely affected under the statute. The Fifth Circuit rejected that narrow interpretation and held that the retailers did, in fact, have standing to challenge the FDA’s order. That decision formed the basis for the appeal before the Supreme Court.

What did the U.S. Supreme Court ultimately decide about standing in regulatory challenges?

In an opinion authored by Justice Amy Coney Barrett, the Supreme Court upheld the Fifth Circuit’s ruling and firmly rejected the FDA’s restrictive reading of who qualifies as “adversely affected.” The Court emphasized that this language—common across various administrative laws—has historically been interpreted broadly. Citing the APA, Justice Barrett wrote that any party “even arguably within the zone of interests to be protected or regulated by the statute” is entitled to judicial review of agency action.

Importantly, the Court explicitly referenced the NCLA’s amicus brief, which laid out the historical and statutory foundations for interpreting “adversely affected” to include third-party stakeholders like retailers. Justice Barrett affirmed that narrowing the definition, as proposed by the FDA, would undercut the judiciary’s role in checking administrative agencies and potentially strip legal recourse from parties suffering genuine commercial or constitutional harm.

The decision not only affirmed the importance of legal access for retailers in this specific vaping case but also served as a broader rejection of executive agencies’ attempts to gatekeep access to the courts.

How does this ruling affect FDA authority and future regulatory challenges in the vaping sector?

While the ruling does not reverse the FDA’s denial of R.J. Reynolds Vapor Company’s marketing application for Vuse e-cigarettes, it significantly reshapes the legal landscape for entities impacted by FDA decisions. The Court’s opinion clarifies that economic actors—whether retailers, distributors, or trade associations—have legitimate standing to challenge agency actions that affect their operations, even if they are not the applicants or direct parties to the regulatory proceeding.

The decision could open the door to increased litigation from affected downstream parties in the vaping industry, a sector already facing aggressive FDA enforcement actions. Since the implementation of the PMTA pathway, the FDA has denied authorization for thousands of vaping products, often citing youth appeal or insufficient evidence on public health impacts. Retailers previously had limited legal pathways to challenge these decisions. That restriction has now been lifted.

Analysts following the vaping and nicotine sector suggest that this ruling introduces a new dimension to litigation strategy and may create uncertainty for how the FDA structures its enforcement priorities in the near term. Institutional observers believe other industries under strict federal oversight—such as pharmaceuticals, environmental compliance, and financial services—may also see downstream stakeholders becoming more proactive in challenging agency determinations.

What are legal experts and civil liberties advocates saying about the impact of this case?

The New Civil Liberties Alliance, which advocates for due process rights and limitations on administrative agency power, released statements highlighting the broader constitutional significance of the Court’s ruling. Daniel Kelly, Senior Litigation Counsel at NCLA, described the outcome as a “welcome affirmation” that agencies cannot manipulate legal definitions to deny access to the courts.

NCLA President Mark Chenoweth remarked that a contrary ruling would have gutted judicial review provisions across multiple statutes and weakened legal accountability in the administrative state. The alliance sees this decision as strengthening the right of businesses and individuals to contest what they view as unlawful or overreaching agency actions.

While legal scholars have varied interpretations of the ruling’s long-term effects, most agree that the Court has reasserted the APA’s foundational principle: that affected parties should not be blocked from judicial relief simply due to procedural technicalities or limited definitions of standing devised by agencies themselves.

How might this ruling shape the future of judicial review and agency accountability in the U.S.?

Institutional investors, regulatory counsel, and business groups are watching closely to determine whether this ruling will catalyze a broader shift in how courts handle administrative cases. By affirming a wide interpretation of “adversely affected” parties, the Supreme Court has potentially expanded the field of stakeholders with standing in future regulatory disputes.

This decision is also seen as part of a growing trend in recent Supreme Court cases aimed at reining in what some legal circles refer to as the “Administrative State.” Recent rulings across environmental, health, and education sectors have questioned agencies’ interpretive latitude and reinforced the role of the judiciary as a check on regulatory discretion.

In the near term, analysts expect a potential uptick in court challenges across heavily regulated sectors. Retailers, distributors, and associations that previously lacked standing may now test these new legal openings, especially when facing economic harm from federal orders. The ripple effects may also impact how agencies draft decisions and frame judicial review clauses in future regulations.